Cortechs.ai announces official support of Nuance PowerScribe 360 in NeuroQuant®

Collaboration provides automatic generation of NeuroQuant volumetric data into radiology reports using PowerScribe® 360

(San Diego, CA) November 30, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that NeuroQuant now supports Nuance PowerScribe ® 360, a technology collaboration will support accurate and automatic field population of PowerScribe 360 reports with NeuroQuant’s volumetric MRI data.

Hospitals, clinics, imaging and research centers worldwide will benefit from this expanded capability, which provides automatic and flexible data integration of NeuroQuant’s 3D T1 MRI brain structure measurements, with Nuance PowerScribe 360, the industry’s most trusted and widely used real-time radiology reporting solution.

“We are excited to work with Nuance to provide our customers with streamlined reporting of NeuroQuant data through PowerScribe 360,” said Guri Stark, Cortechs.ai’ CEO. “We believe this collaboration will significantly benefit many physicians and clinicians using NeuroQuant in increasing productivity and reducing transcription and data entry errors, allowing them to deliver better patient care.”

For more information about using PowerScribe with NeuroQuant, please visit Cortechs.ai at Booth 1861 (Hall A, South) during Radiological Society of North America’s (RSNA) 2015 Annual Meeting (Nov. 29 – Dec. 4, McCormick Place, Chicago).

About Cortechs.ai                                                                                                                                                         

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.  As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.

More Resources

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network
Scroll to Top